Identification of structural fingerprints for ABCG2 inhibition by using Monte Carlo optimization, Bayesian classification, and structural and physicochemical interpretation (SPCI) analysis

References

• E. Roussel, V.K. Tran-Nguyen, K. Bouhedjar, M.A. Dems, A. Belaidi, B. Matougui, B. Peres, A. Azioune, O. Renaudet, P. Falson, and A. Boumendjel, Optimization of the chromone scaffold through QSAR and docking studies: Identification of potent inhibitors of ABCG2, Eur. J. Med. Chem. 184 (2019), pp. 111772. doi:10.1016/j.ejmech.2019.111772.
   PubMed Web of Science ®Google Scholar
• W. Mo and J.T. Zhang, Human ABCG2: Structure, function, and its role in multidrug resistance, Int. J. Biochem. Cell B 3 (2012), pp. 1.
   Google Scholar
• W.J. Li, X.H. Chen, J.C. Zeng, L.L. Duan, Z.H. Liu, and X.H. Sheng, Theoretical insight into the multiple interactions of quinazoline inhibitors with breast cancer resistance protein (BCRP/ABCG2), J. Biomol. Struct. Dyn. (2019), pp. 1–8.
   PubMed Web of Science ®Google Scholar
• R.W. Robey, K.K. To, O. Polgar, M. Dohse, P. Fetsch, M. Dean, and S.E. Bates, ABCG2: A perspective, Adv. Drug Deliv. Rev. 61 (2009), pp. 3–13. doi:10.1016/j.addr.2008.11.003.
   PubMed Web of Science ®Google Scholar
• M.J. Szafraniec, M. Szczygieł, K. Urbanska, and L. Fiedor, Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2), Drug Metab. Rev. 46 (2014), pp. 459–474. doi:10.3109/03602532.2014.942037.
   PubMed Web of Science ®Google Scholar
• M.H. Hasanabady and F. Kalalinia, ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer, J. Biosci. 41 (2016), pp. 313–324. doi:10.1007/s12038-016-9601-5.
   PubMed Web of Science ®Google Scholar
• O. Polgar, R.W. Robey, and S.E. Bates, ABCG2: Structure, function and role in drug response, Expert Opin. Drug Metab. Toxicol. 4 (2008), pp. 1–5. doi:10.1517/17425255.4.1.1.
   PubMed Web of Science ®Google Scholar
• J. Gallus, K. Juvale, and M. Wiese, Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity, Biochim. Biophys. Acta 1838 (2014), pp. 2929–2938. doi:10.1016/j.bbamem.2014.08.003.
   PubMed Web of Science ®Google Scholar
• R.J. Ferreira, C.A. Bonito, M.N. Cordeiro, M.J. Ferreira, and D.J. Dos Santos, Structure-function relationships in ABCG2: Insights from molecular dynamics simulations and molecular docking studies, Sci. Rep. 8 (2018), pp. 1–7. doi:10.1038/s41598-018-24602-w.
   PubMed Web of Science ®Google Scholar
• P. Pavek, G. Merino, E. Wagenaar, E. Bolscher, M. Novotna, J.W. Jonker, and A.H. Schinkel, Human breast cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo (4, 5-b) pyridine, and transport of cimetidine, J. Pharmacol. Exp. Ther. 312 (2005), pp. 144–152. doi:10.1124/jpet.104.073916.
   PubMed Web of Science ®Google Scholar
• M.F. Rosenberg, Z. Bikadi, E. Hazai, T. Starborg, L. Kelley, N.E. Chayen, R.C. Ford, and Q. Mao, Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation, Acta Crystallogr. D Biol. Crystallogr. 71 (2015), pp. 1725–1735. doi:10.1107/S1399004715010676.
   PubMedGoogle Scholar
• M. Videira, R.L. Reis, and M.A. Brito, Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance, Biochim. Biophys. Acta 1846 (2014), pp. 312–325. doi:10.1016/j.bbcan.2014.07.011.
   PubMed Web of Science ®Google Scholar
• B. Bhardwaj, A.T. Baidya, S.A. Amin, N. Adhikari, T. Jha, and S. Gayen, Insight into structural features of phenyltetrazole derivatives as ABCG2 inhibitors for the treatment of multidrug resistance in cancer, SAR QSAR Environ. Res. 30 (2019), pp. 457–475. doi:10.1080/1062936X.2019.1615545.
   PubMed Web of Science ®Google Scholar
• C.W. Murray, M.L. Verdonk, and D.C. Rees, Experiences in fragment-based drug discovery, Trends Pharmacol. Sci. 33 (2012), pp. 224–232. doi:10.1016/j.tips.2012.02.006.
   PubMed Web of Science ®Google Scholar
• S. Jain, S.A. Amin, N. Adhikari, T. Jha, and S. Gayen, Good and bad molecular fingerprints for human rhinovirus 3C protease inhibition: Identification, validation, and application in designing of new inhibitors through Monte Carlo-based QSAR study, J. Biomol. Struct. Dyn. 38 (2019), pp. 66–77. doi:10.1080/07391102.2019.1566093.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, S. Bhargava, T. Jha, and S. Gayen, Structural exploration of hydroxyethylamines as HIV-1 protease inhibitors: New features identified, SAR QSAR Environ. Res. 29 (2018), pp. 385–408. doi:10.1080/1062936X.2018.1447511.
   PubMed Web of Science ®Google Scholar
• R. Gaikwad, S. Ghorai, S.A. Amin, N. Adhikari, T. Patel, K. Das, T. Jha, and S. Gayen, Monte Carlo based modelling approach for designing and predicting cytotoxicity of 2-phenylindole derivatives against breast cancer cell line MCF7, Toxicol. In Vitro 52 (2018), pp. 23–32. doi:10.1016/j.tiv.2018.05.016.
   PubMed Web of Science ®Google Scholar
• J.E. Obreque-Balboa, Q. Sun, G. Bernhardt, B. König, and A. Buschauer, Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization, Eur. J. Med. Chem. 109 (2016), pp. 124–133. doi:10.1016/j.ejmech.2015.12.010.
   PubMed Web of Science ®Google Scholar
• O. Szolomajer-Csikos, E. Beery, L. Kosa, Z. Rajnai, M. Jani, A. Hetenyi, K. TauberJakab, P. Krajcsi, and G.K. Toth, Synthesis and ABCG2 inhibitory activity of novel fumitremorgin C analogs–specificity and structure activity correlations, Med. Chem. 9 (2013), pp. 494–509. doi:10.2174/1573406411309040003.
   PubMed Web of Science ®Google Scholar
• S.C. Koehler, K. Silbermann, and M. Wiese, Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter, Eur. J. Med. 124 (2016), pp. 881–895. doi:10.1016/j.ejmech.2016.09.010.
   Google Scholar
• F. Marighetti, K. Steggemann, M. Karbaum, and M. Wiese, Scaffold identification of a new class of potent and selective BCRP inhibitors, ChemMedChem 10 (2015), pp. 742–751. doi:10.1002/cmdc.201402498.
   PubMed Web of Science ®Google Scholar
• S. Kraege, S.C. Kohler, and M. Wiese, Acryloylphenylcarboxamides: A new class of breast cancer resistance protein (ABCG2) modulators, ChemMedChem 11 (2016), pp. 2422–2435. doi:10.1002/cmdc.201600341.
   PubMed Web of Science ®Google Scholar
• S. Kraege, K. Stefan, S.C. Kohler, and M. Wiese, Optimization of acryloylphenylcarboxamides as inhibitors of ABCG2 and comparison with acryloylphenylcarboxylate, ChemMedChem 11 (2016), pp. 2547–2558. doi:10.1002/cmdc.201600455.
   PubMed Web of Science ®Google Scholar
• S.C. Koehler, S. Vahdati, M.S. Scholz, and M. Wiese, Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors, Eur. J. Med. Chem. 146 (2018), pp. 483–500. doi:10.1016/j.ejmech.2018.01.012.
   PubMed Web of Science ®Google Scholar
• A. Spindler, K. Stefan, and M. Wiese, Synthesis and investigation of tetrahydro-β-carboline derivatives as inhibitors of the breast cancer resistance protein (ABCG2), J. Med. Chem. 59 (2016), pp. 6121–6135. doi:10.1021/acs.jmedchem.6b00035.
   PubMed Web of Science ®Google Scholar
• M.K. Krapf and M. Wiese, Synthesis and biological evaluation of 4-anilino-quinazolines and-quinolines as inhibitors of breast cancer resistance protein (ABCG2), J. Med. Chem. 59 (2016), pp. 5449–5461. doi:10.1021/acs.jmedchem.6b00330.
   PubMed Web of Science ®Google Scholar
• K. Juvale, V.F. Pape, and M. Wiese, Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein, Bioorg. Med. Chem. 20 (2012), pp. 346–355. doi:10.1016/j.bmc.2011.10.074.
   PubMed Web of Science ®Google Scholar
• K. Juvale, J. Gallus, and M. Wiese, Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2), Bioorg. Med. Chem. 21 (2013), pp. 7858–7873. doi:10.1016/j.bmc.2013.10.007.
   PubMed Web of Science ®Google Scholar
• M.K. Krapf, J. Gallus, and M. Wiese, 4-Anilino-2-pyridylquinazolines and-pyrimidines as highly potent and nontoxic inhibitors of breast cancer resistance protein (ABCG2), J. Med. Chem. 60 (2017), pp. 4474–4495. doi:10.1021/acs.jmedchem.7b00441.
   PubMed Web of Science ®Google Scholar
• A.A. Toropov, A.P. Toropova, A. Lombardo, A. Roncaglioni, E. Benfenati, and G. Gini, CORAL: Building up the model for bioconcentration factor and defining it’s applicability domain, Eur. J. Med. Chem. 46 (2011), pp. 1400–1403. doi:10.1016/j.ejmech.2011.01.018.
   PubMed Web of Science ®Google Scholar
• N.M. O’Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch, and G.R. Hutchison, Open Babel: An open chemical toolbox, J. Cheminf. 3 (2011), pp. 33. doi:10.1186/1758-2946-3-33.
   PubMed Web of Science ®Google Scholar
• J. Garcia, P.R. Duchowicz, M.F. Rozas, J.A. Caram, M.V. Mirifico, F.M. Fernandez, and E.A. Castro, A comparative QSAR on 1, 2, 5-thiadiazolidin-3-one 1, 1-dioxide compounds as selective inhibitors of human serine proteinases, J. Mol. Graph. Model. 31 (2011), pp. 9–10. doi:10.1016/j.jmgm.2011.07.007.
   Web of Science ®Google Scholar
• A. Worachartcheewan, P. Mandi, V. Prachayasittikul, A.P. Toropova, A.A. Toropov, and C. Nantasenamat, Large-scale QSAR study of aromatase inhibitors using SMILES-based descriptors, Chemom. Intell. Lab. Syst. 138 (2014), pp. 120–126. doi:10.1016/j.chemolab.2014.07.017.
   Web of Science ®Google Scholar
• A.T. Baidya, K. Ghosh, S.A. Amin, N. Adhikari, J. Nirmal, T. Jha, and S. Gayen, In silico modelling, identification of crucial molecular fingerprints, and prediction of new possible substrates of human organic cationic transporters 1 and 2, New J. Chem. 44 (2020), pp. 4129–4143. doi:10.1039/C9NJ05825G.
   Web of Science ®Google Scholar
• S.C. Manisha, P. Kumar, and A. Kumar, Development of prediction model for fructose-1,6-bisphosphatase inhibitors using the Monte Carlo method, SAR QSAR Environ. Res. 30 (2019), pp. 145–159. doi:10.1080/1062936X.2019.1568299.
   PubMed Web of Science ®Google Scholar
• A.A. Toropov, A.P. Toropova, G. Selvestrel, and E. Benfenati, Idealization of correlations between optimal simplified molecular input-line entry system-based descriptors and skin sensitization, SAR QSAR Environ. Res. 30 (2019), pp. 447–455. doi:10.1080/1062936X.2019.1615547.
   PubMed Web of Science ®Google Scholar
• P. Kumar, A. Kumar, and J. Sindhu, Design and development of novel focal adhesion kinase (FAK) inhibitors using Monte Carlo method with index of ideality of correlation to validate QSAR, SAR QSAR Environ. Res. 30 (2019), pp. 63–80. doi:10.1080/1062936X.2018.1564067.
   PubMed Web of Science ®Google Scholar
• L.L. Liu, J. Lu, Y. Lu, M.Y. Zheng, X.M. Luo, W.L. Zhu, H.L. Jiang, and K.X. Chen, Novel Bayesian classification models for predicting compounds blocking hERG potassium channels, Acta Pharmacol. Sin. 35 (2014), pp. 1093. doi:10.1038/aps.2014.35.
   PubMed Web of Science ®Google Scholar
• H. Zhang, Y.L. Kang, Y.Y. Zhu, K.X. Zhao, J.Y. Liang, L. Ding, T.G. Zhang, and J. Zhang, Novel naïve Bayes classification models for predicting the chemical Ames mutagenicity, Toxicol. In Vitro 41 (2017), pp. 56–63. doi:10.1016/j.tiv.2017.02.016.
   PubMed Web of Science ®Google Scholar
• J. Fang, X. Pang, R. Yan, W. Lian, C. Li, Q. Wang, A.L. Liu, and G.H. Du, Discovery of neuroprotective compounds by machine learning approaches, RSC Adv. 6 (2016), pp. 9857–9871. doi:10.1039/C5RA23035G.
   Web of Science ®Google Scholar
• W. Lian, J. Fang, C. Li, X. Pang, A.L. Liu, and G.H. Du, Discovery of Influenza A virus neuraminidase inhibitors using support vector machine and Naïve Bayesian models, Mol. Divers. 20 (2016), pp. 439–451. doi:10.1007/s11030-015-9641-z.
   PubMed Web of Science ®Google Scholar
• S. Ekins, A.C. Casey, D. Roberts, T. Parish, and B.A. Bunin, Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis, Tuberculosis 94 (2014), pp. 162–169. doi:10.1016/j.tube.2013.12.001.
   PubMedGoogle Scholar
• S.A. Amin, N. Adhikari, S. Bhargava, T. Jha, and S. Gayen, Designing potential antitrypanosomal thiazol-2-ethylamines through predictive regression based and classification based QSAR analyses, Curr. Drug Discov. Technol. 14 (2017), pp. 39–52. doi:10.2174/1570163813666161117144137.
   PubMedGoogle Scholar
• S.A. Amin, N. Adhikari, and T. Jha, Diverse classes of HDAC8 inhibitors: In search of molecular fingerprints that regulate activity, Future Med. Chem. 10 (2018), pp. 1589–1602. doi:10.4155/fmc-2018-0005.
   PubMed Web of Science ®Google Scholar
• P. Polishchuk, O. Tinkov, T. Khristova, L. Ognichenko, A. Kosinskaya, A. Varnek, and V. Kuz’min, Structural and physico-chemical interpretation (SPCI) of QSAR models and its comparison with matched molecular pair analysis, J. Chem. Inf. Model. 56 (2016), pp. 1455–1469. doi:10.1021/acs.jcim.6b00371.
   PubMed Web of Science ®Google Scholar
• P.G. Polishchuk, Simplex representation of molecular structure – A chemoinformatic tool for calculation of simplex descriptors v. 1.1.1. Available at https://github.com/DrrDom/sirms. https://github.com/DrrDom/sirms.
   Google Scholar
• M. Matveieva, M.T. Cronin, and P. Polishchuk, Interpretation of QSAR models: Mining structural patterns taking into account molecular context, Mol. Inform. 38 (2019), pp. 1800084. doi:10.1002/minf.201800084.
   Web of Science ®Google Scholar
• RDKit, Open-Source Cheminformatics 2017.09.1. Available at http://www.rdkit.org.
   Google Scholar